• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早发型子痫前期孕妇 11-13 孕周时母体血浆可溶性内皮糖蛋白水平

Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.

机构信息

Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium.

出版信息

Ultrasound Obstet Gynecol. 2010 Jun;35(6):680-7. doi: 10.1002/uog.7621.

DOI:10.1002/uog.7621
PMID:20205159
Abstract

OBJECTIVES

To examine the performance of screening for pre-eclampsia (PE) by a combination of maternal factors, soluble endoglin (sEng), pregnancy associated plasma protein-A (PAPP-A), placental growth factor (PlGF) and uterine artery lowest pulsatility index (L-PI) at 11-13 weeks' gestation.

METHODS

Uterine artery L-PI, sEng, PAPP-A and PlGF were measured at 11-13 weeks in 90 singleton pregnancies that subsequently developed PE, including 30 that required delivery before 34 weeks (early PE) and 60 with late PE, and 180 unaffected controls. Screening performance for PE by maternal factors, sEng, PAPP-A, PlGF and uterine artery L-PI and their combinations was determined.

RESULTS

In early PE, compared to controls, plasma sEng and uterine L-PI were significantly increased and serum PAPP-A and PlGF were decreased. In late PE, compared to controls, serum PlGF was decreased and uterine L-PI was increased but plasma sEng and serum PAPP-A were not significantly different. In screening for early PE, the detection rate for a 10% false-positive rate was 46.7% for sEng alone and 96.3% for a combination of maternal factors, sEng, PlGF and uterine artery L-PI.

CONCLUSIONS

Effective screening for early PE can be provided by a combination of maternal factors, sEng, PlGF and uterine artery L-PI at 11-13 weeks' gestation.

摘要

目的

探讨在 11-13 孕周时,联合母体因素、可溶性内皮糖蛋白(sEng)、妊娠相关血浆蛋白-A(PAPP-A)、胎盘生长因子(PlGF)和子宫动脉最低搏动指数(L-PI)筛查子痫前期(PE)的效能。

方法

在 90 例单胎妊娠中测量了 11-13 孕周的子宫动脉 L-PI、sEng、PAPP-A 和 PlGF,这些妊娠随后发生了 PE,包括 30 例需要在 34 周前分娩(早发性 PE)和 60 例晚发性 PE,以及 180 例未受影响的对照组。通过母体因素、sEng、PAPP-A、PlGF 和子宫动脉 L-PI 及其组合来确定对 PE 的筛查性能。

结果

在早发性 PE 中,与对照组相比,血浆 sEng 和子宫 L-PI 显著升高,血清 PAPP-A 和 PlGF 降低。在晚发性 PE 中,与对照组相比,血清 PlGF 降低,子宫 L-PI 升高,但血浆 sEng 和血清 PAPP-A 无显著差异。在筛查早发性 PE 时,sEng 单独检测的假阳性率为 10%时的检出率为 46.7%,而母体因素、sEng、PlGF 和子宫动脉 L-PI 联合检测的检出率为 96.3%。

结论

在 11-13 孕周时,联合母体因素、sEng、PlGF 和子宫动脉 L-PI 可以有效筛查早发性 PE。

相似文献

1
Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.早发型子痫前期孕妇 11-13 孕周时母体血浆可溶性内皮糖蛋白水平
Ultrasound Obstet Gynecol. 2010 Jun;35(6):680-7. doi: 10.1002/uog.7621.
2
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.11-13 孕周筛查子痫前期:使用妊娠相关血浆蛋白-A、胎盘生长因子或两者联合。
Ultrasound Obstet Gynecol. 2020 Sep;56(3):400-407. doi: 10.1002/uog.22093. Epub 2020 Aug 5.
3
The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.利用母体血液中的血管生成生物标志物来识别哪些小于胎龄儿需要早产以及哪些母亲会发生先兆子痫。
J Matern Fetal Neonatal Med. 2016;29(8):1214-28. doi: 10.3109/14767058.2015.1048431.
4
Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.双胎妊娠中孕妇因素和生物标志物在 11-13 孕周预测子痫前期:EVENTS 试验数据。
Ultrasound Obstet Gynecol. 2021 Feb;57(2):257-265. doi: 10.1002/uog.23531.
5
Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.孕 11-13 周时通过母体因素和生物标志物筛查子痫前期。
Ultrasound Obstet Gynecol. 2018 Aug;52(2):186-195. doi: 10.1002/uog.19112. Epub 2018 Jul 11.
6
Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.妊娠高血压疾病:11-13 周时通过子宫动脉多普勒、血压和血清 PAPP-A 联合筛查。
Prenat Diagn. 2010 Mar;30(3):216-23. doi: 10.1002/pd.2440.
7
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.妊娠高血压疾病:11-13 周的生物物理和生化标志物筛查。
Ultrasound Obstet Gynecol. 2010 Jun;35(6):662-70. doi: 10.1002/uog.7628.
8
Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.根据 11-13 孕周的母体因素和生物标志物,对双胎妊娠子痫前期进行筛查的竞争风险模型。
Ultrasound Obstet Gynecol. 2017 Nov;50(5):589-595. doi: 10.1002/uog.17531. Epub 2017 Sep 25.
9
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia.孕11⁺⁰至13⁺⁶周母体血清胎盘生长因子预测子痫前期的研究
Ultrasound Obstet Gynecol. 2008 Nov;32(6):732-9. doi: 10.1002/uog.6244.
10
Diagnostic accuracy of first-trimester combined screening for early-onset and preterm pre-eclampsia at 8-10 compared with 11-13 weeks' gestation.早发型和早产子痫前期的孕早期联合筛查在 8-10 周与 11-13 周妊娠时的诊断准确性比较。
Ultrasound Obstet Gynecol. 2021 Jan;57(1):84-90. doi: 10.1002/uog.22071.

引用本文的文献

1
Maternal angiogenic factor disruptions prior to clinical diagnosis of preeclampsia: insights from the REVAMP study.子痫前期临床诊断前的母体血管生成因子紊乱:来自 REVAMP 研究的见解。
Hypertens Res. 2024 Sep;47(9):2532-2548. doi: 10.1038/s41440-024-01775-8. Epub 2024 Jul 4.
2
Evaluation of Serum Biomarkers and Other Diagnostic Modalities for Early Diagnosis of Preeclampsia.子痫前期早期诊断的血清生物标志物及其他诊断方法评估
J Family Reprod Health. 2019 Jun;13(2):56-69.
3
Protein Misfolding during Pregnancy: New Approaches to Preeclampsia Diagnostics.
妊娠期蛋白质错误折叠:子痫前期诊断的新方法。
Int J Mol Sci. 2019 Dec 7;20(24):6183. doi: 10.3390/ijms20246183.
4
Pre-eclampsia and the foetus: a cardiovascular perspective.子痫前期与胎儿:心血管视角
Cardiovasc J Afr. 2018 Nov/Dec;29(6):387-393. doi: 10.5830/CVJA-2017-039.
5
The prediction of early preeclampsia: Results from a longitudinal proteomics study.早发性子痫前期的预测:一项纵向蛋白质组学研究的结果。
PLoS One. 2019 Jun 4;14(6):e0217273. doi: 10.1371/journal.pone.0217273. eCollection 2019.
6
Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia.综合系统生物学方法鉴定子痫前期的新的母体和胎盘途径。
Front Immunol. 2018 Aug 8;9:1661. doi: 10.3389/fimmu.2018.01661. eCollection 2018.
7
Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.二甲双胍,21世纪的阿司匹林:其在妊娠期糖尿病、子痫前期和癌症预防以及促进长寿方面的作用。
Am J Obstet Gynecol. 2017 Sep;217(3):282-302. doi: 10.1016/j.ajog.2017.06.003. Epub 2017 Jun 12.
8
Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.早发型和晚发型子痫前期发病前母体血浆可溶性ST2浓度升高——一项纵向研究
J Matern Fetal Neonatal Med. 2018 Feb;31(4):418-432. doi: 10.1080/14767058.2017.1286319. Epub 2017 Mar 1.
9
Dysregulated circulating miRNAs in preeclampsia.子痫前期中循环miRNA失调
Biomed Rep. 2016 Dec;5(6):686-692. doi: 10.3892/br.2016.779. Epub 2016 Oct 14.
10
Prediction of Small for Gestational Age Infants in Healthy Nulliparous Women Using Clinical and Ultrasound Risk Factors Combined with Early Pregnancy Biomarkers.使用临床和超声风险因素结合早期妊娠生物标志物预测健康初产妇的小于胎龄儿
PLoS One. 2017 Jan 9;12(1):e0169311. doi: 10.1371/journal.pone.0169311. eCollection 2017.